D. Beyer

C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.

A. Więcek, H. Haller, D. Eulberg, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The pharmacokinetics of subcutaneously injected bimosiamose disodium in healthy male volunteers

G. Wolff, B. Jilma, K. Vollhardt, 2007, Biopharmaceutics & drug disposition.

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

R. Greil, R. Foà, I. Yakoub-Agha, 2017, Leukemia.

EFFECTS OF THE PAN-SELECTIN ANTAGONIST BIMOSIAMOSE (TBC1269) IN EXPERIMENTAL HUMAN ENDOTOXEMIA

G. Wolff, J. Leitner, B. Jilma, 2007, Shock.

Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects

N. Halama, D. Jäger, D. Eulberg, 2021, Journal for ImmunoTherapy of Cancer.

C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria

A. Więcek, H. Haller, D. Eulberg, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males.

G. Wolff, B. Jilma, K. Beeh, 2007, British journal of clinical pharmacology.

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia

R. Foà, M. Gobbi, M. Steurer, 2019, Haematologica.

Rational design of novel, potent small molecule pan-selectin antagonists.

G. Wolff, B. Heinemann, R. Kranich, 2007, Journal of medicinal chemistry.

Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer

N. Halama, D. Eulberg, A. Mangasarian, 2019, Annals of Oncology.